On the first day of work in the Spring Festival, leaders visited the New Year.
Release time:
2020-08-14
On the first day of work in the Spring Festival, the leaders visited the New Year
News 2# July 23 . On the first day of work after the Spring Festival holiday, the leaders of the group company paid New Year greetings to all employees of overseas enterprises through the video conference system, and separately visited the subordinate enterprises in Jin to extend holiday greetings to the employees. The management team of
Group Company extended New Year greetings to all employees of overseas enterprises such as Daye Peak and Yunnan Peak through the video conference system. The new year is the 14th anniversary of the peak start-up 60#. The challenges of the external market, the changes in the national economic situation and the increasingly fierce competition in the industry have all brought pressure to the company's production and operation activities. The group leaders hope that all the peak people will work together to seize the opportunity, seriously organize the production and operation work, and present the 16th anniversary of the peak start-up 60. At the same time, Daye Peak and Yunnan Peak are in the annual overhaul stage. During the overhaul process, the safety string should be tightened to complete the overhaul work as soon as possible. After , the leaders of the group company visited the subordinate enterprises in Jin separately to understand the implementation of the annual work plan and put forward requirements and hopes for the work in the new year.
Chairman Jiang Xiaomeng and other leaders visited Jianfeng Pharmacy, Jinhua Pharmaceutical Company and International Trading Company successively. In the peak pharmacy, Jiang Xiaomeng visited the warehouse site and exchanged views with the management team of the pharmacy on the layout of the newly opened pharmacy and the income of grass-roots employees. In communicating with the management team of the pharmaceutical company, Jiang Xiaomeng hopes that everyone will strengthen their confidence, devote themselves to all kinds of work with full enthusiasm, positive work attitude and pragmatic work style, correctly handle the strategic adjustment after the implementation of the "two-vote system", and lay the foundation for the development of
. At the construction site of the international trade bonded warehouse project, Jiang Xiaomeng learned about the progress of the project on the spot and put forward guidance and requirements for the project construction. General Manager Yu Jianhong and other leaders visited Qiubin Pharmaceutical Factory, Cable Company, Jianfeng Health Technology Company and Jinxi Pharmaceutical Factory successively. In Qiubin Factory, Yu Jianhong learned about the resumption of production in the workshop and visited the office site of the Product Development Department, asking the Development Department to do a good job in redecorating the office space. Yu Jianhong visited the production site of the cable company and the central control room of the peak health planting workshop to learn about the production orders and startup of the workshop after the festival. In Jinxi Factory, Yu Jianhong asked pharmaceutical companies to actively enhance their advantages in the region, speed up the implementation of project land, and promote the progress of internationalization. The central laboratory should correspondingly increase equipment and facilities and introduce personnel to ensure the research and development of new products and normal production needs. (Fan Tufa, Qian Fang, Zhang An, Wang Haibin, Chen Daiyou, Ye Haiyun)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page